Key facts
- Notable investors include Caleb Capital, Guohai Innovation Capital Investment Management.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Keze Yongxin
- ·The full record, as it builds
Funding rounds
No funding rounds for Keze Yongxin are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Keze Yongxin
Manufacturer of biochemical raw materials and RNA backbone components designed to support nucleic acid research and therapeutic development. The company offers nucleoside monomers, phosphoramidites, mRNA excipients, delivery systems including LNP and GalNAc, and customized synthesis of fluorinated, peptide, boronic acid, cholesterol, and heterocyclic compounds, enabling pharmaceutical and biotechnology companies to advance nucleic acid-based drug development with reliable materials and optimised processes.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2023
- Website
- cincobio.com/
- Ownership
- Privately Held (backing)
Keze Yongxin doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Keze Yongxin shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Keze Yongxin in its N-PORT filings yet. We sweep new filings monthly.